Phaseline

Targets › HPV18

HPV18: drug programs, companies and trials

12 programs from 11 companies in 18 trials: 10 Phase 3, 6 Phase 4, 1 Phase 2, 1 Phase 1; Infectious disease, Oncology, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: the race on HPV18, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Miquel Angel Pavon RibasNonavalent HPV vaccine (9vHPV/Gardasil-9™)
Virus-like particles (VLPs) of HPV major capsid L1 protein from 9 HPV types that generate
HPV6, HPV11, HPV16, HPV18, HPV31Phase 4Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)Dec 2026
National Cancer Institute (NCI)Recombinant Human Papillomavirus Bivalent Vaccine
Bivalent HPV vaccine (HPV 16/18 L1 VLP/AS04)
HPV16, HPV18Phase 4Human Papillomavirus-Related Cervical Carcinoma; Human Papillomavirus InfectionJan 2027
The University of Texas Medical Branch, Galveston9-valent HPV vaccine, 2 doses alternate timing
Recombinant human papillomavirus vaccine targeting 9 HPV types
HPV5, HPV6, HPV11, HPV16, HPV18Phase 4ImmunizationAug 2027
International Agency for Research on CancerCERVAVAC quadrivalent HPV vaccine
Quadrivalent HPV vaccine targeting HPV types 6, 11, 16, and 18
HPV6, HPV11, HPV16, HPV18Phase 4Vaccine EffectivenessDec 2028
Erasmus Medical CenterGardasil 9 Suspension for Injection
Nonavalent HPV vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58
HPV5, HPV11, HPV16, HPV18Phase 4Vulvar HSILDec 2028
Merck & Co. (MSD)9-valent human papillomavirus (9vHPV) vaccine (Types 6, 11, 16, 18, 31, 33, 45,
Aluminum-adjuvanted recombinant protein vaccine containing virus-like particles of recombi
HPV6, HPV11, HPV16, HPV18, HPV31Phase 3Papillomavirus Infections; Genital WartsJan 2027
Shanghai Bovax Biotechnology9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recom
9-valent HPV recombinant vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
HPV6, HPV11, HPV16, HPV18, HPV31Phase 3Genital Wart; Cervical CancerJul 2027
Xiamen UniversityNonavalent HPV vaccine (6,11,16,18,31,33,45,52,58 Type)
Recombinant human papillomavirus vaccine targeting 9 HPV types
HPV6, HPV11, HPV16, HPV18, HPV31Phase 3Cervical Intraepithelial NeoplasiaDec 2027
Beijing Health Guard BiotechnologyRecombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (H
Recombinant nonavalent HPV vaccine targeting 9 HPV types
HPV6, HPV11, HPV16, HPV18, HPV31Phase 3Human Papillomavirus InfectionMar 2028
National Vaccine and Serum Institute, ChinaQuadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
Recombinant human papillomavirus vaccine (HPV types 6, 11, 16, 18)
HPV6, HPV11, HPV16, HPV18Phase 3Human Papillomavirus (HPV) InfectionJul 2032
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinspBI-11
HPV16/18-targeted therapeutic DNA vaccine
HPV16, HPV18Phase 2HPV InfectionNov 2028
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPVX7
Therapeutic HPV vaccine (pBI-11 DNA + TA-HPV)
HPV16, HPV18Phase 1Cervical CancerJun 2029

Conditions

Papillomavirus Infections (4) Human Papillomavirus Infection (2) Cervical Cancer (2) Genital Warts (1) Cervical Intraepithelial Neoplasia (1) Immunization (1) HPV Infection (1) Human Papillomavirus-Related Cervical Carcinoma (1) Vulvar HSIL (1) Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) (1) Genital Wart (1) Vaccine Effectiveness (1)

Modalities

other (7), mixed (2), small molecule (2), protein or peptide (1)

Companies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) Merck & Co. (MSD) (1) Xiamen University (1) The University of Texas Medical Branch, Galveston (1) Beijing Health Guard Biotechnology (1) National Cancer Institute (NCI) (1) Erasmus Medical Center (1) Miquel Angel Pavon Ribas (1) Shanghai Bovax Biotechnology (1) International Agency for Research on Cancer (1) National Vaccine and Serum Institute, China (1)

Related targets

HPV16 (12) HPV11 (9) HPV6 (8) HPV31 (5) HPV5 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.